Cardiovascular safety and benefits of GLP-1 receptor agonists
| Autor: | Niels B. Dalsgaard, Filip K. Knop, Andreas Brønden, Tina Vilsbøll |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
endocrine system
medicine.medical_specialty Glucagon-Like Peptides 030209 endocrinology & metabolism Type 2 diabetes Disease 030204 cardiovascular system & hematology Pharmacology Hypoglycemia Glucagon-Like Peptide-1 Receptor 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine Weight loss Risk Factors Medicine Humans Hypoglycemic Agents Pharmacology (medical) Intensive care medicine Glycemic business.industry Liraglutide Semaglutide General Medicine medicine.disease chemistry Diabetes Mellitus Type 2 Cardiovascular Diseases medicine.symptom business medicine.drug |
| Zdroj: | Expert opinion on drug safety. 16(3) |
| ISSN: | 1744-764X |
| Popis: | Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) constitute a class of drugs for the treatment of type 2 diabetes, and currently, six different GLP-1RAs are approved. Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia. Treatment with the GLP-1RA lixisenatide has been shown to be safe in patients with type 2 diabetes and recent acute coronary syndrome. Furthermore, liraglutide and semaglutide have been shown to reduce cardiovascular (CV) disease (CVD) risk in type 2 diabetes patients with established and/or high risk of CVD. The CV safety of the remaining GLP-1RAs in type 2 diabetes patients with established and/or high risk of CVD remains uncertain, but ongoing CV outcome trials (CVOTs) will elucidate this within a few years. Areas covered: The aim of this review is to provide an overview of the existing GLP-1RAs with a particular focus on their clinical effects on CV risk factors and their CV safety and benefits. Expert opinion: Data on the CV risks and benefits associated with GLP-1RA treatment in patients with type 2 diabetes and high risk of CVD are emerging - and look promising (especially for liraglutide and semaglutide). Data from ongoing CVOTs will be crucial for the positioning of the individual GLP-1RAs in the treatment of patients with type 2 diabetes and high risk of CVD. However, the long-term CV safety and the potential of GLP-1RAs to prevent CVD in type 2 diabetes patients with less risk of CVD (e.g. newly diagnosed patients) remain uncertain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|